Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma

PR Newswire August 16, 2022

Nektar Therapeutics Reports Second Quarter 2022 Financial Results

PR Newswire August 4, 2022

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

PR Newswire July 26, 2022

Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer

PR Newswire July 1, 2022

Nektar Therapeutics Reports First Quarter 2022 Financial Results

PR Newswire May 5, 2022

Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook

PR Newswire April 25, 2022

Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT(TM) and CIBMTR®

PR Newswire April 23, 2022

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan

PR Newswire April 22, 2022

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)

PR Newswire April 14, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

PR Newswire March 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Newsfile March 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

PR Newswire March 16, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Newsfile March 15, 2022

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

PR Newswire March 14, 2022

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

Business Wire March 14, 2022

Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results

PR Newswire February 28, 2022

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets

PR Newswire February 17, 2022

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

PR Newswire January 5, 2022

Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis

PR Newswire December 15, 2021

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting

PR Newswire December 13, 2021